A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs Binimetinib (Primary) ; Carboplatin; Pemetrexed
- Indications Carcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- 25 Oct 2019 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
- 25 Oct 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2020.
- 20 May 2019 Planned End Date changed from 1 Apr 2019 to 1 Jun 2019.